🇺🇸 FDA
Patent

US 12421316

Bispecific immunotoxins targeting human CD25+CCR4+ tumors and regulatory T-cells

granted A61KA61K45/06A61P

Quick answer

US patent 12421316 (Bispecific immunotoxins targeting human CD25+CCR4+ tumors and regulatory T-cells) held by The Regents of the University of Colorado, a Body Corporate expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of Colorado, a Body Corporate
Grant date
Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K45/06, A61P, A61P35/00